莫西沙星治疗慢性支气管炎急性发作疗效与安全性的Meta分析

发布时间：2018-11-12 13:31

【摘要】：目的:系统评价莫西沙星(MFX)治疗慢性支气管炎急性发作(AECB)的疗效和安全性,为临床合理应用MFX提供循证参考。方法:计算机检索Pub Med、EMBase、Cochrane图书馆、Medline、中国生物医学文献数据库、相关期刊论文、中文科技期刊数据库和万方数据库,并手工检索相关会议论文集和灰色文献等,纳入MFX(试验组)对比其他抗菌药物(对照组)治疗AECB的随机对照试验(RCT),按照纳入与排除标准选择文献、提取资料和评价质量后,采用Rev Man 5.2统计软件进行Meta分析,同时应用意向性分析(Intention-to-treat analysis,ITT分析)和符合方案集分析(Per-protocol analysis,PP分析)两种方法。结果:共纳入14项RCT,合计6 058例患者。PP分析结果显示,试验组患者临床有效率与对照组相当[RR=1.02,95%CI(1.00,1.04),P=0.06],而细菌清除率显著高于对照组[RR=1.07,95%CI(1.04,1.11),P0.001]。ITT分析结果显示,试验组患者临床有效率显著高于对照组[RR=1.03,95%CI(1.00,1.06),P=0.03],而细菌清除率[RR=1.02,95%CI(0.92,1.12),P=0.73]和不良反应发生率[RR=0.97,95%CI(0.87,1.08),P=0.52]与对照组比较,差异均无统计学意义。结论:MFX治疗AECB的疗效不劣于其他抗菌药物,安全性与其他抗菌药物相当。
[Abstract]:Objective: to evaluate the efficacy and safety of moxifloxacin (MFX) in the treatment of chronic bronchitis with acute attack of (AECB), and to provide evidence-based reference for rational clinical application of MFX. Methods: Pub Med,EMBase,Cochrane library, Medline, Chinese biomedical literature database, Chinese journal full-text database, Chinese sci-tech journal database and Wanfang database were searched by computer. The randomized controlled trial (RCT), which was included in MFX (test group) and compared with other antimicrobial agents (control group), selected the literature according to the inclusion and exclusion criteria, extracted the data and evaluated the quality, and then used Rev Man 5.2 statistical software to carry out Meta analysis. At the same time, two methods of intentionality analysis (Intention-to-treat analysis,ITT analysis) and coincidence scheme set analysis (Per-protocol analysis,PP analysis) are applied. Results: a total of 6 058 patients with 14 items of RCT, were included. The results of PP analysis showed that the clinical effective rate of the patients in the trial group was equal to that in the control group [RR=1.02,95%CI (1.00 卤1.04), RR=1.02,95%CI 0.06]. But the bacterial clearance rate was significantly higher than that in the control group [RR=1.07,95%CI (1.04 卤1.11), P0.001]. The results of ITT analysis showed that the clinical effective rate of the test group was significantly higher than that of the control group [RR=1.03,95%CI (1.00 ~ 1.06), P _ (0.03)]. However, the bacterial clearance rate [RR=1.02,95%CI (0.92 卤1.12), P < 0.73] and the incidence of adverse reactions [RR=0.97,95%CI (0.87 卤1.08), P < 0.52] were not significantly different from those of the control group. Conclusion: the efficacy of MFX in the treatment of AECB is not inferior to that of other antimicrobial agents, and its safety is equal to that of other antimicrobial agents.
【作者单位】：广州医科大学附属第二医院药学部;汕头大学医学院第一附属医院药学部;
【基金】：国家科技支撑计划子课题(No.2013BAI06B04)
【分类号】：R562.21

【相似文献】